Angiotensin receptor‐neprilysin inhibitor attenuates cardiac hypertrophy and improves diastolic dysfunction in a mouse model of heart failure with preserved ejection fraction

Zhang, Yue; Meng, Yuanlin; Suo, Yang; Yang, Qian; Shao, Shuai; Liu, Ying; Wang, Yuanyuan; Bao, Qiankun; Liu, Tong; Li, Guangping

doi:10.1111/1440-1681.13672

Cited by 4 publications

(3 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies have shown that sacubitril-valsartan improved cardiac diastole function by reducing ventricular hypertrophy and fibrosis in mice. The potential underlying mechanism is that sacubitril-valsartan effectively suppresses the transmission of signals involved in calcium-mediated calcineurin-nuclear factor of activated T cell pathways [ 23 ].…”

Section: Pharmacological and Non-pharmacological Treatments Of Hfpefmentioning

confidence: 99%

Pharmacological and Non-Pharmacological Advancements in Heart Failure Treatment

Wang,

Fu,

Wang

et al. 2024

Rev. Cardiovasc. Med.

View full text Add to dashboard Cite

Heart failure (HF) is a complex, life-threatening condition characterized by high mortality, morbidity, and poor quality of life. Despite studies of epidemiology, pathogenesis, and therapies, the rate of HF hospitalization is still increasing due to the growing and aging population and an increase in obesity in relatively younger individuals. It remains a predominant issue in the public health and the global economic burden. Current research has focused on how HF affects the entire range of left ventricular ejection fraction (LVEF), especially the three HF subgroups. This review provides a latest overview of pharmacological and non-pharmacological strategies of these three subgroups (HF with preserved ejection fraction, HF with reduced ejection fraction, and HF with mildly reduced ejection fraction). We summarize conventional therapies, investigate novel strategies, and explore the new technologies such as aortic thoracic stimulation and interatrial shunting devices.

show abstract

Section: Pharmacological and Non-pharmacological Treatments Of Hfpefmentioning

confidence: 99%

Pharmacological and Non-Pharmacological Advancements in Heart Failure Treatment

Wang,

Fu,

Wang

et al. 2024

Rev. Cardiovasc. Med.

View full text Add to dashboard Cite

show abstract

“…The European Society of Cardiology's medical guidelines have recently been amended. They currently recommend (Class I) the use of LCZ696, an angiotensin receptor-neprilysin inhibitor (ARNI), to minimize mortality as well as morbidity among individuals with HF with reduced ejection fraction (HFrEF) [ 2 , 3 ]. LCZ696 is a composite of sacubitril and valsartan, possessing the molecular components of both drugs [ 3 ].…”

Section: Introductionmentioning

confidence: 99%

“…They currently recommend (Class I) the use of LCZ696, an angiotensin receptor-neprilysin inhibitor (ARNI), to minimize mortality as well as morbidity among individuals with HF with reduced ejection fraction (HFrEF) [ 2 , 3 ]. LCZ696 is a composite of sacubitril and valsartan, possessing the molecular components of both drugs [ 3 ]. The combined medication of sacubitril/valsartan has the ability to hinder the activity of both neprilysin and angiotensin receptors.…”

Section: Introductionmentioning

confidence: 99%

Effects of Angiotensin Receptor-Neprilysin Inhibitors Versus Enalapril or Valsartan on Patients With Heart Failure: A Systematic Review and Meta-Analysis

Jain,

Meyur,

Wadhwa

et al. 2023

Cureus

View full text Add to dashboard Cite

Recent studies have focused on treating heart failure, primarily mitigating symptoms and reducing the risk of mortality and other cardiovascular complications. A promising new treatment approach involves using LCZ696, an angiotensin receptor-neprilysin inhibitor (ARNI) comprising sacubitril and valsartan. This treatment is superior to the conventional drugs enalapril or valsartan in patients diagnosed with heart failure. A systematic search was conducted on PubMed, the Cochrane Library, and Elsevier’s ScienceDirect databases to identify studies comparing sacubitril/valsartan with other drugs in heart failure patients with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF). The analyses were conducted using the random-effects model. The study's primary outcomes included all-cause mortality, death from cardiovascular causes, first hospitalization for heart failure, congestive heart failure, and changes in the Kansas City Cardiomyopathy Questionnaire (KCCQ) clinical score. The pooled analysis showed that treatment with the sacubitril/valsartan combination was associated with a significantly decreased rate of first hospitalization for heart failure (RR: 0.86; 95% CI: 0.79, 0.98, p: 0.03; I2: 57%) and significantly increased KCCQ clinical score (WMD: 2.20; 95% CI: 0.33, 4.06, p: 0.02; I2: 100%). However, the two groups had no significant difference in all-cause mortality (RR: 0.90; 95% CI: 0.80, 1.01, p: 0.08; I2: 20%), death from cardiovascular causes (RR: 0.96; 95% CI: 0.87, 1.05, p: 0.34; I2: 0%), or congestive heart failure (RR: 0.97; 95% CI: 0.75, 1.25, p: 0.19; I2: 38%). The research findings suggest that sacubitril/valsartan (LCZ696) reduces hospitalizations due to heart failure and improves KCCQ clinical scores. This treatment also reduces the decline in renal function and side effects associated with enalapril or valsartan. Nonetheless, further high-quality randomized controlled trials with large sample sizes are needed to assess other impacts of this therapy on heart failure patients. Overall, the use of LCZ696 represents a promising new approach to the treatment of heart failure.

show abstract